PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Arixa Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 9 granted patents across 6 technology areas, active 2018–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07D (HETEROCYCLIC COMPOUNDS).

Explore the portfolio See the ranking
9
Total patents granted
6
CPC technology areas
21.4
Avg claims per patent
+25%
5-year filing velocity

The verdict

Arixa holds 9 US patents across 6 technology areas, rank #28,153 of 50,000 tracked assignees.

#28,153
of 50,000 US assignees by volume
Top 65%
by Innovation Score (30.6/100)
21.4
avg claims per patent
+25%
filing velocity, last 5 yrs

Portfolio overview

Arixa Pharmaceuticals, Inc. has been granted 9 US utility patents between 2018 and 2023, placing Arixa Pharmaceuticals, Inc. at rank #28,153 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.4 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a US Corporation, Arixa Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Arixa sits between Arcis Biotechnology Holdings Limited (9 patents, rank #28,149) and Armagen, Inc. (9 patents, rank #28,157) - the closest US assignees by grant volume. The composite Innovation Score of 30.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 5 grants, compared with 4 in the 2015–2019 window, a +25% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Arixa Pharmaceuticals, Inc.'s 21.4 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Arixa Pharmaceuticals, Inc. against peers pursuing similar technology classes.

Who files at Arixa's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Arixa holds 9 patents at rank #28,153, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Arixa

By rank, the assignees closest to #28,153 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Arixa's primary technology class.

Arixa's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

31 Top 65% higher than 35% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 20182019202020212023 1
USPTO utility patent grants by year · 2018–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table
Arixa Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2018 2 22.2%
2019 2 22.2%
2020 2 22.2%
2021 2 22.2%
2023 1 11.1%

Which technologies does Arixa Pharmaceuticals, Inc. patent most?

Top 6 of 6 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Growing

Where it ranks

Overall rank by patents

#28,153

Across all tracked assignees

Innovation Score

30.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Arixa Pharmaceuticals, Inc. hold?
Arixa Pharmaceuticals, Inc. holds 9 US granted patents filed between 2018 and 2023, spanning 6 technology areas.
What is Arixa Pharmaceuticals, Inc.'s Innovation Score?
Arixa Pharmaceuticals, Inc. has an Innovation Score of 30.6 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Arixa Pharmaceuticals, Inc. focus on?
Arixa Pharmaceuticals, Inc.'s top technology area is C07D (HETEROCYCLIC COMPOUNDS) with 9 patents. The company has filed patents in 6 CPC subclasses total.
Is Arixa Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
Arixa Pharmaceuticals, Inc.'s recent filing velocity is +25% compared to the prior five-year period. The company is maintaining or growing its patent output.
What does claim depth mean for Arixa Pharmaceuticals, Inc.'s patents?
Arixa Pharmaceuticals, Inc.'s patents average 21.4 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Arixa Pharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Arixa's 9 grants land it in the top 65% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Arixa ranks #28,153 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C07D - see who else leads that technology area. C07D leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.